Prostate Radiotherapy in the Era of Advanced Imaging and Precision Medicine

Table 1

Randomized controlled trials evaluating the efficacy of radiation dose escalation for prostate cancer.

Trial	, inclusion criteria	Dose comparison (Gray)	Outcome
MD Anderson [35]	301; cT1-3 N0 M0	70 versus 78	78% versus 59% Freedom from biochemical or clinical failure
PROG 95-09 [37]	393; cT1b-2b, PSA ≤ 15	70.2 versus 79.2	32% versus 17% 10-year biochemical failure
MRC RT01 [39]	843; cT1b-3a N0 M0, PSA < 50	64 versus 74	43% versus 55% 10-year biochemical recurrence-free survival
Dutch [36]	664; cT1b-4	68 versus 78	54% versus 64% Freedom from failure
GETUG 06 [38]	306; cT1b-3a N0 M0, PSA < 50	70 versus 80	39% versus 28% Biochemical failure

PSA: prostate specific antigen.